Clearing and Masking Agents in Pretargeting Strategies

Research output: Contribution to journal › Review › Research › peer-review

Standard

Clearing and Masking Agents in Pretargeting Strategies. / Staudt, Markus; Herth, Matthias M.

In: Pharmaceuticals, Vol. 16, No. 4, 497, 2023.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Staudt, M & Herth, MM 2023, 'Clearing and Masking Agents in Pretargeting Strategies', Pharmaceuticals, vol. 16, no. 4, 497. https://doi.org/10.3390/ph16040497

APA

Staudt, M., & Herth, M. M. (2023). Clearing and Masking Agents in Pretargeting Strategies. Pharmaceuticals, 16(4), [497]. https://doi.org/10.3390/ph16040497

Vancouver

Staudt M, Herth MM. Clearing and Masking Agents in Pretargeting Strategies. Pharmaceuticals. 2023;16(4). 497. https://doi.org/10.3390/ph16040497

Author

Staudt, Markus ; Herth, Matthias M. / Clearing and Masking Agents in Pretargeting Strategies. In: Pharmaceuticals. 2023 ; Vol. 16, No. 4.

Bibtex

@article{fd73c3299b524c6da60406b111904cc4,
title = "Clearing and Masking Agents in Pretargeting Strategies",
abstract = "{\textquoteleft}Pretargeting{\textquoteright} led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.",
keywords = "bioorthogonal, clearing agents, masking agents, pretargeting, tetrazine ligation",
author = "Markus Staudt and Herth, {Matthias M.}",
note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",
year = "2023",
doi = "10.3390/ph16040497",
language = "English",
volume = "16",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "M D P I AG",
number = "4",

}

RIS

TY - JOUR

T1 - Clearing and Masking Agents in Pretargeting Strategies

AU - Staudt, Markus

AU - Herth, Matthias M.

N1 - Publisher Copyright: © 2023 by the authors.

PY - 2023

Y1 - 2023

N2 - ‘Pretargeting’ led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

AB - ‘Pretargeting’ led to increased target-to-background ratios of nanomedicines in short timeframes. However, clearing or masking agents are needed to reach the full potential of pretargeted approaches. This review gives an overview of clearing and masking agents employed in pretargeting strategies in both preclinical and clinical settings and discusses how these agents work.

KW - bioorthogonal

KW - clearing agents

KW - masking agents

KW - pretargeting

KW - tetrazine ligation

U2 - 10.3390/ph16040497

DO - 10.3390/ph16040497

M3 - Review

C2 - 37111254

AN - SCOPUS:85154573666

VL - 16

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 4

M1 - 497

ER -

ID: 346407935